Skip to content
Disclosery

ARCH Venture Management, LLC

Follow

13F filer, CIK 1274403, CHICAGO, IL

ARCH Venture Management, LLC reported $492,363,653 across 9 holdings for the quarter ended 2025-09-30, in a 13F-HR filed 2025-11-14.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001012975-25-000787

Period
2025-09-30
Reported value
$492M
Holdings
9
Top 10 weight
100%
New
0
Sold out
2

Largest buys vs the previous quarter

SecurityShares changeApprox. value
LYELadded+938,438$15.2M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
VERVE THERAPEUTICS INCexited-2,008,809-$22.6M
UNITY BIOTECHNOLOGY INC COM…exited-1,004,817-$386K

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q3 2025

Share positions as resolved from 13F-HR 0001012975-25-000787, largest first. % of portfolio is the value over $492,363,653, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
RAPPRAPPORT THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 3,728,738 shares; 2024Q4: 3,728,738 shares; 2025Q1: 3,728,738 shares; 2025Q2: 3,728,738 shares; 2025Q3: 3,728,738 shares 3,728,738$111M22.49%0Timeline
BEAMBEAM THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 4,834,653 shares; 2024Q4: 4,540,132 shares; 2025Q1: 4,540,132 shares; 2025Q2: 4,540,132 shares; 2025Q3: 4,540,132 shares 4,540,132$110M22.38%0Timeline
MAZEMAZE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 4,120,053 shares; 2025Q2: 4,120,053 shares; 2025Q3: 4,120,053 shares 4,120,053$107M21.7%0Timeline
VIRVIR BIOTECHNOLOGY INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 12,916,663 shares; 2025Q3: 12,916,663 shares 12,916,663$73.8M14.98%0Timeline
LYELLYELL IMMUNOPHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 1,820,634 shares; 2025Q3: 2,759,072 shares 2,759,072$44.8M9.1%+938,438Timeline
ERASERASCA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 11,055,554 shares; 2024Q4: 11,055,554 shares; 2025Q1: 11,055,554 shares; 2025Q2: 11,055,554 shares; 2025Q3: 11,055,554 shares 11,055,554$24.1M4.89%0Timeline
GOSSGOSSAMER BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 8,055,916 shares; 2024Q4: 8,055,916 shares; 2025Q1: 8,055,916 shares; 2025Q2: 8,055,916 shares; 2025Q3: 8,055,916 shares 8,055,916$21.2M4.3%0Timeline
QTTBQ32 BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 320,482 shares; 2024Q4: 320,482 shares; 2025Q1: 320,482 shares; 2025Q2: 320,482 shares; 2025Q3: 320,482 shares 320,482$635K0.13%0Timeline
CEROCERO THERAPEUTICS HLDGS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 22,389 shares; 2025Q3: 22,389 shares 22,389$114K0.02%0Timeline

Sold out in Q3 2025

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
VERVE THERAPEUTICS INCVERVE THERAPEUTICS INC2,008,809$22.6Mshares
UNITY BIOTECHNOLOGY INC COM…UNITY BIOTECHNOLOGY INC COM NEW1,004,817$386Kshares

How Q3 2025 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001012975-25-000787 base2025-11-14acceptance time not in the bulk data set